Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
ApexOnco Front Page
Recent articles
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
A single-arm trial was enough for J&J’s Inlexzo nod.
